We have located links that may give you full text access.
ENGLISH ABSTRACT
JOURNAL ARTICLE
[An analysis of causes of death in patients with Parkinson's disease].
AIM: To determine population mortality rate and reasons of death in Parkinson's disease (PD).
MATERIAL AND METHODS: To analyze reasons of death, medical death certificates and postmortem records as well as official results of the Federal state statistics service were used. According to the register of Parkinson's disease (PD) patients during 2009-2012, the total mortality was 9.9%. The average age of patients died from the disease was 74.3 ± 2.4 years. The main reasons of death were PD (36.2%), circulatory illnesses (27.6%), respiratory diseases (12.1%), malignant neoplastic diseases (12.1%), other reasons (12.0%). Direct reasons of death in patients with PD were the complications of underlying disease in connection with the development of immobility and comorbidities. Timely correction of complications and comorbidities is a main strategy to extend life expectancy in patients with PD.
MATERIAL AND METHODS: To analyze reasons of death, medical death certificates and postmortem records as well as official results of the Federal state statistics service were used. According to the register of Parkinson's disease (PD) patients during 2009-2012, the total mortality was 9.9%. The average age of patients died from the disease was 74.3 ± 2.4 years. The main reasons of death were PD (36.2%), circulatory illnesses (27.6%), respiratory diseases (12.1%), malignant neoplastic diseases (12.1%), other reasons (12.0%). Direct reasons of death in patients with PD were the complications of underlying disease in connection with the development of immobility and comorbidities. Timely correction of complications and comorbidities is a main strategy to extend life expectancy in patients with PD.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app